337 related articles for article (PubMed ID: 24820265)
1. Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line.
Ashizawa T; Akiyama Y; Miyata H; Iizuka A; Komiyama M; Kume A; Omiya M; Sugino T; Asai A; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
Int J Oncol; 2014 Jul; 45(1):411-8. PubMed ID: 24820265
[TBL] [Abstract][Full Text] [Related]
2. YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.
Akiyama Y; Ashizawa T; Komiyama M; Miyata H; Oshita C; Omiya M; Iizuka A; Kume A; Sugino T; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
Oncol Rep; 2014 Jul; 32(1):159-66. PubMed ID: 24842123
[TBL] [Abstract][Full Text] [Related]
3. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.
Ashizawa T; Miyata H; Iizuka A; Komiyama M; Oshita C; Kume A; Nogami M; Yagoto M; Ito I; Oishi T; Watanabe R; Mitsuya K; Matsuno K; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Nakasu Y; Yamaguchi K; Akiyama Y
Int J Oncol; 2013 Jul; 43(1):219-27. PubMed ID: 23612755
[TBL] [Abstract][Full Text] [Related]
4. Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line.
Miyata H; Ashizawa T; Iizuka A; Kondou R; Nonomura C; Sugino T; Urakami K; Asai A; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K; Akiyama Y
Cancer Genomics Proteomics; 2017 Jan; 14(1):83-91. PubMed ID: 28031240
[TBL] [Abstract][Full Text] [Related]
5. The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line.
Akiyama Y; Nonomura C; Ashizawa T; Iizuka A; Kondou R; Miyata H; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Asai A; Ito M; Kiyohara Y; Yamaguchi K
Immunol Lett; 2017 Oct; 190():20-25. PubMed ID: 28716484
[TBL] [Abstract][Full Text] [Related]
6. miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway.
Li H; Chen L; Li JJ; Zhou Q; Huang A; Liu WW; Wang K; Gao L; Qi ST; Lu YT
J Hematol Oncol; 2018 May; 11(1):70. PubMed ID: 29843746
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of STAT3 enhances the radiosensitizing effect of temozolomide in glioblastoma cells in vitro and in vivo.
Han TJ; Cho BJ; Choi EJ; Kim DH; Song SH; Paek SH; Kim IA
J Neurooncol; 2016 Oct; 130(1):89-98. PubMed ID: 27510952
[TBL] [Abstract][Full Text] [Related]
9. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X
Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
[TBL] [Abstract][Full Text] [Related]
11. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
[TBL] [Abstract][Full Text] [Related]
12. PomGnT1 enhances temozolomide resistance by activating epithelial-mesenchymal transition signaling in glioblastoma.
Liu Q; Xue Y; Chen Q; Chen H; Zhang X; Wang L; Han C; Que S; Lou M; Lan J
Oncol Rep; 2017 Nov; 38(5):2911-2918. PubMed ID: 29048655
[TBL] [Abstract][Full Text] [Related]
13. Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
Li H; Yuan X; Yan D; Li D; Guan F; Dong Y; Wang H; Liu X; Yang B
Cell Physiol Biochem; 2017; 42(3):1192-1201. PubMed ID: 28668966
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A).
Choi J; Lee JH; Koh I; Shim JK; Park J; Jeon JY; Yun M; Kim SH; Yook JI; Kim EH; Chang JH; Kim SH; Huh YM; Lee SJ; Pollak M; Kim P; Kang SG; Cheong JH
Oncotarget; 2016 Oct; 7(40):65643-65659. PubMed ID: 27582539
[TBL] [Abstract][Full Text] [Related]
15. Growth-inhibitory and chemosensitizing effects of microRNA-31 in human glioblastoma multiforme cells.
Zhou RJ; Xu XY; Liu BX; Dai WZ; Cai MQ; Bai CF; Zhang XF; Wang LM; Lin L; Jia SZ; Wang WH
Int J Mol Med; 2015 Oct; 36(4):1159-64. PubMed ID: 26310668
[TBL] [Abstract][Full Text] [Related]
16. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
[TBL] [Abstract][Full Text] [Related]
17. Noscapine inhibits tumor growth in TMZ-resistant gliomas.
Jhaveri N; Cho H; Torres S; Wang W; Schönthal AH; Petasis NA; Louie SG; Hofman FM; Chen TC
Cancer Lett; 2011 Dec; 312(2):245-52. PubMed ID: 21925789
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation.
Ashizawa T; Miyata H; Ishii H; Oshita C; Matsuno K; Masuda Y; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Akiyama Y
Int J Oncol; 2011 May; 38(5):1245-52. PubMed ID: 21369699
[TBL] [Abstract][Full Text] [Related]
19. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN
Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979
[TBL] [Abstract][Full Text] [Related]
20. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]